HC Wainwright decreased their price target on shares of Mirum Pharmaceuticals from $69.00 to $61.00 and set a “buy” rating on the stock in a research note on Wednesday, February 15th.

Source: https://www.etfdailynews.com/2023/02/24/connor-clark-lunn-investment-management-ltd-sells-3784-shares-of-mirum-pharmaceuticals-inc-nasdaqmirm/

HC Wainwright reiterated a “buy” rating and issued a $61.00 price objective on shares of Mirum Pharmaceuticals in a research note on Thursday, April 6th.

Source: https://www.etfdailynews.com/2023/05/29/clearbridge-investments-llc-grows-stake-in-mirum-pharmaceuticals-inc-nasdaqmirm/

Polar Capital Holdings Plc purchased a new position in Mirum Pharmaceuticals in the first quarter valued at approximately $21,441,000.

Source: https://www.etfdailynews.com/2023/08/10/analysts-set-expectations-for-mirum-pharmaceuticals-inc-s-q3-2023-earnings-nasdaqmirm/